ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atorvastatin

Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.

Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.

Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 30, 2005105 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only290 open or runningphase 4since Aug 30, 2005Aug 25, 2005none ahead
Organonits history only200 open or runningphase 4since Apr 1, 2008Sep 23, 2004none ahead
Pfizer160 open or runningphase 4since Sep 6, 2005Aug 22, 2005none ahead
Chong Kun Dang Pharmaceuticalits history only60 open or runningphase 4since Nov 16, 2009Nov 16, 2009none ahead
Dr. Reddy's Laboratoriesits history only60 open or runningphase 1since Jul 18, 2012Jul 18, 2012none ahead
GlaxoSmithKlineits history only60 open or runningphase 3since Dec 15, 2011Dec 11, 2006none ahead
Astellas Pharmaits history only30 open or runningphase 4since Dec 5, 2006Dec 5, 2006none ahead
Daiichi Sankyoits history only30 open or runningphase 4since Sep 16, 2008Sep 16, 2008none ahead
midas-pharma-gmbhits history only20 open or runningphase 1since Jan 23, 2020Jan 23, 2020none ahead
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since Dec 20, 2011Dec 20, 2011none ahead

Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2005First studies: 9 phase 3 studiesFirst studyNCT00134498, NCT00134485, NCT00134264 and 6 more
  2. Sep 6, 20052 phase 4 studies in Cardiovascular DiseasesNCT00147602, NCT00159835
  3. May 16, 20062 phase 4 studiesNCT00327691, NCT00327418
  4. Sep 26, 2006Phase 4 study in Coronary Artery DiseaseNCT00380939 · 600 enrolled · United States
  5. Jan 23, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT03031119 · 62 enrolled · Belgium
  6. Oct 13, 2021Phase 1 study in Healthy AdultsNCT05093205 · 35 enrolled · United States

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

All 16 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05093205Healthy Adults · United States1CompletedJul 6, 202235
NCT03031119Non-alcoholic Fatty Liver Disease · Belgium1CompletedJul 201762
NCT00380939Coronary Artery Disease · United States4Completed600
NCT00327691Cardiovascular Diseases · United States, Australia, Austria and more4Completed8,600
NCT00327418Stroke · United Kingdom4Completed2,800
NCT00159835Cardiovascular Diseases · Denmark, Finland, Iceland and more4Completed8,600
NCT00147602Cardiovascular Diseases · Australia, Austria, Belgium and more4Completed4,732
NCT00145431Hyperlipoproteinemia Type III · United States, Canada3TerminatedDec 200641
NCT00138762Hyperlipidemias · United States, Belgium, Germany and more3CompletedAug 20063,800
NCT00137462Hyperlipidemias · United States, Canada3Completed900
NCT00136981Hyperlipoproteinemia Type II · United States, Canada, Czech Republic and more3Completed800
NCT00134498Hypertriglyceridemia · United States, Canada3Completed160
NCT00134485Hyperlipoproteinemia Type II · United States, Australia, Canada and more3Completed400
NCT00134264Coronary Disease · United States, Australia, Canada and more3TerminatedJun 200715,067
NCT00134238Hyperlipoproteinemia Type II · United States, Canada, Czech Republic and more3TerminatedDec 2006755
NCT00134173Coronary Disease · United States, Belgium, Canada and more3Completed1,100

How it is read

Names in the registry

  • “Atorvastatin”, 95 entries
  • “atorvastatin”, 36 entries
  • “Atorvastatin 20 mg”, 3 entries
  • “Comparator: atorvastatin”, 3 entries
  • “Atorvastatin 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.